Key result
The use of autologous materials in aortic valve surgery has evolved significantly, culminating in the widespread adoption of glutaraldehyde-treated autopericardium for neocuspidisation.
Why the study?
To describe the historical development and evolution of various autologous materials used in heart valve surgery, particularly aortic valve reconstruction.
This historical review outlines the evolution of autologous materials in aortic valve surgery, highlighting the pivotal role of glutaraldehyde-treated autopericardium in modern reconstructive techniques.
Historical review informs autologous valve options; leaves open modern comparative trials.
Various types of autologous materials are used in heart valve surgery, particularly the aortic valve, and this article describes their historical development. The evolution of the use of various autogenous tissues, such as the aortic wall, fascia lata of the thigh, pericardium and others is described and discussed in detail. This paper presents the results of experimental and clinical publications devoted to the surgical techniques and the outcomes of heart valve reconstruction using such materials. The negative aspects of the use of a wide range of autografts are discussed, including the short service life and low strength, which led to declining interest in this group of reconstructive interventions. The method for treating the autopericardium with glutaraldehyde, proposed in 1986 by C.S. Love, J.W. Love and colleagues, raised the use of autologous materials in the reconstruction of heart valves to a new level, allowing surgeons to strengthen the autopericardial flaps and increase resistance to hemodynamic stress. Many surgeons, their interest in such treatment methods increased by this discovery, then reported their observations and further developed ways of using the treated autopericardium in aortic valve surgery. Particularly, the method of neocuspidisation of the aortic valve, introduced into wide practice by M.G. Duran and S. Ozaki, has become the quintessential reconstructive valve surgery involving the use of autologous materials.Received 14 March 2021. Revised 26 April 2021. Accepted 27 April 2021.Funding: The study did not have sponsorship.Conflict of interest: The authors declare no conflicts of interests.Contribution of the authorsConception and study design: A.O. Simonyan, A.M. IsmailbaevDrafting the article: A.O. Simonyan, A.M. Ismailbaev, N.O. Kurasov, M.I. TcheglovCritical revision of the article: R.N. Komarov, V.V. Dalinin, I.A. BorisovFinal approval of the version to be published: R.N. Komarov, A.O. Simonyan, I.A. Borisov, V.V. Dalinin, A.M. Ismailbaev, N.O. Kurasov, M.I. Tcheglov
No takes yet. Share an insight, caveat, or question.
Комаров et al. (2021) conducted a review in Heart valve disease requiring surgery. Autologous materials (e.g., glutaraldehyde-treated autopericardium) was evaluated. The use of autologous materials in aortic valve surgery has evolved significantly, culminating in the widespread adoption of glutaraldehyde-treated autopericardium for neocuspidisation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: